Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Type 2 Diabetes With Mild Cognitive Impairment
NCT07711171Phase 4Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Fudan University. Primary endpoint: Changes in cerebral blood flow shown by fMRI at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07711171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711171.